Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azathioprine is an immunosuppressive small molecule that acts as a prodrug for 6-mercaptopurine, which inhibits DNA synthesis and suppresses T-lymphocyte activity. Corticosteroids are a class of steroid hormones that bind to the glucocorticoid receptor to exert potent anti-inflammatory and immunosuppressive effects. This combination regimen is specifically studied by the All India Institute of Medical Sciences (AIIMS) for the treatment of parthenium dermatitis, a severe form of airborne contact dermatitis caused by the weed *Parthenium hysterophorus*. The protocol evaluates the efficacy of azathioprine (administered either as a daily dose or a weekly pulse) in conjunction with topical corticosteroids to induce and maintain disease remission while minimizing the side effects associated with long-term systemic steroid use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azathioprine + corticosteroids.